This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2003 Aug 1;9(8):2882-6.

Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy

Matthew W Harding¹

Affiliations

PMID: 12912931

Review

Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy

Matthew W Harding. Clin Cancer Res. 2003.

. 2003 Aug 1;9(8):2882-6.

Author

Matthew W Harding¹

Affiliation

¹ Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts 02139, USA.

PMID: 12912931

No abstract available

PubMed Disclaimer

Comment on

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, Hidalgo M. Peralba JM, et al. Clin Cancer Res. 2003 Aug 1;9(8):2887-92. Clin Cancer Res. 2003. PMID: 12912932

Similar articles

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, Hidalgo M. Peralba JM, et al. Clin Cancer Res. 2003 Aug 1;9(8):2887-92. Clin Cancer Res. 2003. PMID: 12912932
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP. Ronellenfitsch MW, et al. Brain. 2009 Jun;132(Pt 6):1509-22. doi: 10.1093/brain/awp093. Epub 2009 May 4. Brain. 2009. PMID: 19416948
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS. Amornphimoltham P, et al. Cancer Res. 2005 Nov 1;65(21):9953-61. doi: 10.1158/0008-5472.CAN-05-0921. Cancer Res. 2005. PMID: 16267020
mTOR and cancer: reason for dancing at the crossroads?
Thomas GV. Thomas GV. Curr Opin Genet Dev. 2006 Feb;16(1):78-84. doi: 10.1016/j.gde.2005.12.003. Epub 2005 Dec 15. Curr Opin Genet Dev. 2006. PMID: 16359855 Review.
An expanding role for mTOR in cancer.
Guertin DA, Sabatini DM. Guertin DA, et al. Trends Mol Med. 2005 Aug;11(8):353-61. doi: 10.1016/j.molmed.2005.06.007. Trends Mol Med. 2005. PMID: 16002336 Review.

See all similar articles

Cited by

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib.
Coppin C. Coppin C. Biologics. 2010 May 25;4:91-101. doi: 10.2147/btt.s6748. Biologics. 2010. PMID: 20531964 Free PMC article.
Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis.
Wei W, Peng R, Kuang L, Xu C, Cao Y, Zeng L, Wen X, Qin Q, Zheng C, Li W, Xia S. Wei W, et al. Oncol Lett. 2020 Jan;19(1):261-270. doi: 10.3892/ol.2019.11094. Epub 2019 Nov 14. Oncol Lett. 2020. PMID: 31897138 Free PMC article.
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity.
Fisher R, Larkin J, Swanton C. Fisher R, et al. EPMA J. 2011 Dec 22;3(1):1. doi: 10.1007/s13167-011-0137-3. EPMA J. 2011. PMID: 22738081 Free PMC article.
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, Haque S, Sima CS, Cullen G, Fagin JA, Pfister DG. Sherman EJ, et al. Cancer. 2017 Nov 1;123(21):4114-4121. doi: 10.1002/cncr.30861. Epub 2017 Jun 29. Cancer. 2017. PMID: 28662274 Free PMC article. Clinical Trial.
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.
Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, Gyorffy B, Torrance CJ, Boehme KA, Volkmer H, Toschi L, Nicke B, Beck M, Szallasi Z. Swanton C, et al. Genome Med. 2010 Aug 11;2(8):53. doi: 10.1186/gm174. Genome Med. 2010. PMID: 20701793 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Miscellaneous
- NCI CPTAC Assay Portal